Search Results
Your search for can matches 13490 pages
Showing 1301 - 1350PSMA PET/CT Imaging May Eliminate the Need for Preimaging Biopsy in Older Patients Undergoing Screening for Prostate Cancer
Prostate-specific membrane antigen positron-emission tomography/computed tomography (PSMA PET/CT) imaging may help physicians diagnose advanced disease and select the appropriate therapeutic interventions in patients aged 80 years or older with suspected prostate cancer, according to a recent study ...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
Genitourinary Oncology 2023 Almanac
It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Expert Point of View: Julio Chavez, MD
Julio Chavez, MD, a hematologist at Moffitt Cancer Center, Tampa, Florida, commented on the updated results from the MAGNOLIA trial. “MAGNOLIA was a phase II trial that included patients with marginal zone lymphoma after one or more prior lines of therapy. At the ASH meeting, we heard updated...
Expert Point of View: Ann S. LaCasce, MD, MMSc
Formal discussant of the SWOG S1826 abstract, Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, Boston, said she was “excited” by these results. “The data speak for themselves. Nivolumab plus AVD [doxorubicin, vinblastine, dacarbazine] should be the treatment of choice, with more...
Hematologic Oncology 2023 Almanac
The past several months have brought significant advances within the field of hematologic oncology. Here we will review some key updates focusing on pivotal clinical trials and new drug approvals. Advances in Lymphoma Presented at the 2023 ASCO Annual Meeting, SWOG S1826 compared nivolumab plus...
T-Cell Tolerant Fraction May Predict Immune-Related Adverse Events Among Patients Receiving Immunotherapy
Researchers have identified a novel parameter of T cells that may help oncologists anticipate which patients are most likely to develop immunotherapy toxicity. The findings, published by Ostmeyer in the Journal for ImmunoTherapy of Cancer, could lead to improved treatments for a variety of ...
Are Immune Checkpoint Inhibitors Efficacious Among Patients With Penile Squamous Cell Carcinoma?
Penile squamous cell carcinoma is a rare type of penile cancer with limited treatment options. An international study has found that the use of immune checkpoint inhibitors may offer clinical benefits for some patients with advanced penile squamous cell carcinoma. These findings were published by...
AI-Driven Muscle Mass Assessment May Aid in Detecting Sarcopenia in Patients With Head and Neck Cancer
Researchers have found a way to use artificial intelligence (AI) to diagnose sarcopenia in patients with head and neck cancer. The tool may be used to improve treatment and supportive care for patients, according to a report published by Ye et al in JAMA Network Open. “Sarcopenia is an indicator...
American Society for Radiation Oncology Names Newly Elected Officers to Board of Directors
The members of the American Society for Radiation Oncology (ASTRO) recently elected three new officers to ASTRO’s Board of Directors: Sameer Keole, MD, FASTRO, as President-Elect; Wendy Woodward, MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S. Kavadi, MD, MBA, FASTRO, as Health Policy...
Overcoming Financial Toxicity From Cancer
I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...
Susan M. Love, MD, MBA, Breast Cancer Surgeon, Researcher, and Advocate
Susan M. Love, MD, MBA, a renowned surgeon, author, researcher, and patient advocate who dedicated her life’s work to breast cancer care, died on July 2, 2023, at her home in Los Angeles. The cause of death was recurrent leukemia. She was 75. Born in Long Branch, New Jersey, on February 9, 1948,...
CAR T-Cell Therapies: Trends and Indications
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
Alcohol Consumption and Risk of Breast Cancer Recurrence
A report published by Kwan et al in the journal Cancer provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol? The findings suggest drinking alcohol is not associated with an increased risk of...
New World Economic Forum Research Identifies Top AI Applications That Could Revolutionize Global Health Care
A new World Economic Forum report released June 26, 2023, highlights the transformative potential of artificial intelligence (AI) in health care and the importance of public-private collaboration in driving its global adoption.1 The report—“Scaling Smart Solutions With AI in Health: Unlocking...
Cancer Care Providers Applaud New Federal Rule Regulating Short-Term Limited Duration Plans
On July 7, 2023, the Department of Health and Human Services (HHS), Department of Labor, and the Treasury Department issued a proposed rule regulating the availability of short-term limited duration insurance plans. The rule would restrict the availability of these plans to no more than 4 months....
ASCO Awarded $11 Million to Study Oral Drug Dosing Strategies in Older Adults With Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
ASCO has been awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. The study aims to address a critical evidence gap in the treatment of this...
Expert Point of View: Daniel G. Stover, MD
Formal discussant Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, said the SONIA and PALMIRA trials raised several questions. Can CDK4/6 inhibitors be personalized and differentiated? Can patients delay treatment with these agents? Should all patients receive a...
Should CDK4/6 Inhibitors Be a First-Line Option for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer?
Two studies presented at the 2023 ASCO Annual Meeting challenge the use of CDK4/6 inhibitors as part of upfront treatment of advanced hormone receptor–positive, HER2-negative breast cancer. The first, the SONIA trial, found that first-line treatment with CDK4/6 inhibitors led to greater toxicity...
On the Art of Organizing Best of ASCO Meetings
Preparing and running a medical conference is usually a complex but rewarding mission. It is a demanding job that is typically done voluntarily by physicians and educators who are dedicated to professional and community service; advancement of research and education; as well as the dissemination of ...
How Multidisciplinary Specialties Are Coming Together to Improve the Quality of Life of Cancer Survivors
As we detailed in our Special Report “Surviving, but Not Always Thriving, After Cancer,” in the May 25, 2023, issue of The ASCO Post, the combination of advances in more effective therapies to treat cancer, gains in early detection, and sharp declines in tobacco use have led to a staggering 33%...
Expert Point of View: Barbara Pistilli, MD
The invited discussant of the study by Bar et al, Barbara Pistilli, MD, Head of the Breast Cancer Unit at Gustave Roussy Cancer Center, Villejuif, France, noted that third-generation antibody-drug conjugates, such as fam-trastuzumab deruxtecan-nxki (T-DXd), are showing activity across a wide range ...
HER2-Low Status Is ‘Dynamic’ for Patients With Triple-Negative Breast Cancer
The probability of obtaining a HER2-low test result increases with the number of biopsies performed, according to a study of more than 500 biopsy samples in patients with triple-negative breast cancer. For patients originally labeled as having no HER2 expression (HER2 0), each successive biopsy...
Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns
New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...
Translating Consent Documents: Potential Barrier for Including Underrepresented Groups in Clinical Trials
Cancer research centers conducting clinical trials could potentially enroll more patients from underrepresented racial and ethnic groups by placing a greater emphasis on relieving investigators of the costs of translating consent documents into languages other than English, according to a study...
How Does BMI Affect Cardiac Health for Patients With Breast Cancer Receiving Chemotherapy?
A study covering the northeast region of Colombia found nearly 12% of patients with a high body mass index (BMI) being treated for breast cancer at a regional center experienced cardiotoxicity during chemotherapy. The study will be presented at the upcoming American College of Cardiology Latin...
Wildfire Exposure and Survival Outcomes After Surgery for NSCLC
Investigators have found that exposure to wildfires within 1 year of surgery may significantly lower the chance of survival in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Zhang et al in JAMA Oncology. Background Lung cancer is the second most common...
Comparison of Outcomes of Surgical vs Nonsurgical Approaches in Patients With Malignant Bowel Obstructions
Researchers have compared the efficacy of surgical and nonsurgical interventions for patients with malignant bowel obstructions, according to a recent study published by Krouse et al in The Lancet Gastroenterology & Hepatology. The new findings may help to inform clinical decision-making in the ...
Early-Stage Cancer Diagnoses in the United States May Have Decreased During the First Year of the COVID-19 Pandemic
Investigators have found that monthly U.S. adult cancer diagnoses decreased by 50% early in April 2020 and that the largest decreases were observed for stage I tumors, resulting in a higher proportion of late-stage cancer diagnoses, according to a recent study published by Han et al in The Lancet...
Neoadjuvant FOLFOX vs Chemoradiotherapy in Locally Advanced Rectal Cancer
As reported in The New England Journal of Medicine by Deb Schrag, MD, MPH, FASCO, and colleagues, the phase III PROSPECT trial has shown neoadjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) was noninferior in disease-free survival vs chemoradiotherapy among patients with locally advanced...
Researchers Characterize Adverse Immune Events in Patients With Cancer Who Experience Immune Checkpoint Inhibitor–Associated Arthritis
Researchers may have uncovered the immune adverse events and the specific type of CD8 T cells that characterize inflammatory arthritis induced by immune checkpoint inhibitors, according to a recent study published by Wang et al in Science Immunology. Immune checkpoint inhibitors used to treat...
Gilteritinib Maintenance Therapy After Transplantation in Patients With FLT3-ITD AML Who Have Measurable Residual Disease
A new therapeutic option is under study for use in a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to a presentation during the European Hematology Association (EHA) 2023 Hybrid Congress.1 Exploratory results of the phase III MORPHO trial showed a benefit to the ...
Researchers May Have Uncovered Two New Subtypes of HPV-Positive Head and Neck Squamous Cell Carcinomas
Human papillomavirus (HPV)–positive head and neck squamous cell carcinomas can be divided into two distinct subtypes that may help determine how well patients will respond to therapy, according to a novel study published by Schrank et al in PNAS. The findings also identified a new mechanism of HPV...
Can an AI-Based Tool Accurately Detect Precancerous Cervical Lesions?
Researchers in Japan have developed an artificial intelligence (AI)-based diagnostic tool for colposcopy examinations that may accurately identify cervical intraepithelial neoplasia (CIN) and subsequently suggest appropriate biopsy sites. The research will be presented by Ueda et al at the 2023...
Exercise May Reduce Sexual Dysfunction Caused by Prostate Cancer Treatment
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer, according to a new study conducted in Australia. The research was presented by Galvao et al at the 2023 ASCO Breakthrough meeting (Abstract 71) in Yokohama, Japan. “Sexual dysfunction is a ...
Expert Point of View: Anand Ashwin Patel, MD
As presented at the 2023 ASCO Annual Meeting, the phase III IMerge trial of imetelstat1 and the phase III COMMANDS trial of luspatercept2 met their primary endpoints of transfusion independence. The findings suggest that lower-risk patients with transfusion-dependent, non-del(5q) myelodysplastic...
Patients in Lower-Income Communities May Be Less Likely to Receive CT Colonography Than Those in Higher-Income Communities
Patients who reside in lower-income communities may be less likely to undergo colorectal cancer screenings with computed tomography (CT) colonography than those who reside in higher-income communities, according to a new study published by Christensen et al in the American Journal of ...
Study Finds Durvalumab Plus Carboplatin and Paclitaxel Effective, Tolerable in Frail Patients With Head and Neck Cancer
As a first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, the PD-L1 inhibitor durvalumab plus weekly carboplatin and paclitaxel provided clinically significant efficacy in the phase II FRAIL-IMMUNE (GORTEC 2018-03) trial.1 This regimen may prove to be an effective...
Early-Phase Study Reports Activity of Cabozantinib and Cetuximab Combination in Refractory Head and Neck Cancer
In a phase I study from Memorial Sloan Kettering Cancer Center (MSK), New York, the combination of cabozantinib and cetuximab showed antitumor efficacy in heavily pretreated patients with recurrent or metastatic head and neck squamous cell cancer.1 Antoine Desilets, MD, an advanced oncology fellow ...
Skin Cancer Screenings and Melanoma Outcomes Among Racial and Ethnic Minority Patients
Increased skin cancer screenings may not reduce disparities in the survival rates of patients with melanoma who have darker skin tones, according to a recent study published by Smith et al in JAMA Dermatology. Background Although melanoma—the leading cause of skin cancer mortality—is most common...
The Role of U.S. Cancer Centers in Preparing Patients With Cancer for Climate Change Emergencies
Investigators have proposed that cancer centers may be uniquely positioned to protect communities and patients with cancer from climate-driven disasters by bolstering climate change–associated emergency preparedness, according to a recent study published by Espinel et al in the Journal of the...
